Phase 2 N=39 Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer
Gastric Cancer
Primary: Grade 3 or Higher Toxicity Incidence on Step 1 — 65.8 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=42 Safety and Efficacy Study of Pertuzumab to Treat Castration-Resistant Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants With a Best Overall Confirmed Response of Complete Response (CR) or Partial Response (PR) Based on Response Evaluation Criteria in Solid…
Phase 2 N=5 A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia
Leukaemia, Lymphoblastic
Primary: Number of Participants With a Best Response of Either Complete Remission (CR), Nodular Partial Remission (nPR), Complete Remission-incomplete (CRi) or Partial Remission…
Phase 2 N=11 Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
Myeloma
Primary: Maximum Tolerated Dose (MTD) of Siltuximab — 8.3 mg/kg
Phase 2 N=8 Incretin Effect and Use After Clinical Islet Transplantation
Type 1 Diabetes
Primary: The Primary Endpoint Will be Insulin Independence After 6 Months of Therapy. — 0.25 proportion of participants — p=< 0.05
Phase 2 N=110 Minimally Invasive Surgery and rtPA for Intracerebral Hemorrhage Evacuation
Intracerebral Hemorrhage
Primary: Safety Outcome Number 1: Rate of Mortality — 9.5; 14.8; 7.1 percentage of participants — p=0.324
Phase 2 N=24 Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
Age-related Macular Degeneration
Primary: Highest Tolerated Dose (HTD) of AGN-150998 — 4.2 mg
Phase 2 N=45 Alkaline Water in Reducing Skin Toxicity in Women With Breast Cancer Undergoing Radiation Therapy
Radiation Toxicity · Recurrent Breast Cancer · Stage I Breast Cancer
Primary: Acute and Grade 2 or Higher Radiation-related Skin Toxicity as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 — 38; 38 percentage of…
Phase 2 N=33 Sodium Nitrite to Treat Arterial Aging
Vascular Aging
Primary: Baseline and Week 10 Flow-Mediated Dilation — 3.120; 4.307; 3.118; 3.740 %Change
Phase 2 N=6 BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)
GBM · Glioblastoma Multiforme · Gliosarcoma
Primary: Response Rate (Progression) for Patients With Glioblastoma That Have Progressed After Prior Treatment That Has Included Radiation, Temozolomide and Bevacizumab. — 6…
Phase 2 N=45 Safety and Effectiveness of Kovacaine Nasal Spray for Dental Anesthesia
Dental Anesthesia Efficacy
Primary: Pulpal Anesthesia — 25; 14 participants
Phase 2 N=210 Study of CB-183,315 in Participants With Clostridium Difficile Infection
Clostridium Difficile Infection · Diarrhea
Primary: Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment — 61; 58; 59 participants
Phase 2 N=38 CARNIVAL Type I: Valproic Acid and Carnitine in Infants With Spinal Muscular Atrophy (SMA) Type I
Spinal Muscular Atrophy Type I
Primary: Laboratory Safety Data
Phase 2 N=73 Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat
Moderate or Severe Submental Fullness
Primary: Number of Participants With Adverse Events — 24; 13; 20; 14 participants
Phase 2 N=69 Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Diffuse Astrocytoma
Primary: Maximum Tolerated Dose (Phase I) — 15 mg